ESA Risk Mitigation Strategy Requires Training, Patient Consent, Documentation
FDA Approved More Than 50 New Indications For Cancer In 32 Months, Analysis Finds
FDA Approves Rituxan For CLL
Trending Stories
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation - Group chairs propose funding strategy to jump-start correlative studies
- 2024 Lasker Awards honor discoveries in antitumor immunity, GLP-1-based drugs, and research, advocacy in HIV/AIDS
- A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Karen Knudsen to leave ACS